deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Ea
Scientists at deCODE genetics (NASDAQ:DCGN) today present the discovery of two single letter variations in the sequence of the human genome (SNPs) conferring substantial increased risk of thyroid cancer.